Media mentions

<p>Aleix Prat (IDIBAPS), Roger Gomis (IRB Barcelona) and Juan Miguel Cejalvo (PhD student in the joint programme PhD4MD)</p>
21 Apr 2017 - El Periódico & other media

"El Periódico" and other media, report on a recent study that reveals the biological changes in breast cancer between the primary tumour and metastasis. 

Published in the journal Cancer Research, this work describes for the first time that the longer the time between the diagnosis of the primary tumour and the onset of metastasis is, the more aggressive the cancer becomes.

The first author of the study is Juan Miguel Cejalvo, PhD student of the PhD4MD programme led by Aleix Prat at IDIBAPS and ICREA researcher Roger Gomis at IRB Barcelona.

Link to ...

<p>Meritxell Rovira. Image: Adrià Costa.</p>
16 Apr 2017 - Nació Digital

The Newspaper Nació Digital interviews Meritxell Rovira, visiting scientist in the Biomedical Genomics Lab at IRB Barcelona, about her research on pancreatic stem cells. The best of biomedical research is that "it is interdisciplinary: chemistry, medicine, and biology... Nobody is good enough to know enough, and that is very fortunate," she stresses. 

The interview also reveals a personal side to this scientist, as she explains what has learned about living with breast cancer.

Link to Nació Digital

<p>Fran Supek is starting his Genome Data Science (aGENDAS) laboratory at IRB Barcelona.</p>
15 Apr 2017 - El Punt AVUI

The local newspaper “El Punt Avui” has included an article about IRB Barcelona's new laboratory for analysis of genomic 'big data', entitled Genome Data Science (aGENDAS).

aGENDAS, headed by Fran Supek, is starting this April and will undertake research in Big Data, a strategic area also for the Barcelona Institute of Science and Technology (BIST).

Link to La Vanguardia

14 Apr 2017 - La Sexta-Noticias

La Sexta newscast team has covered the research performed by IDIBAPS Biomedical Research Institute and IRB Barcelona scientists on a new strategy to achieve genetically modified viruses that selectively attack tumor cells without affecting healthy tissues.

"As it is based on mechanisms that do not exist at all in healthy tissue, the oncoselectivity in the animal models we have used is complete", explains ICREA researcher Raúl Méndez, head of the Translational Control of Cell Cycle and Differentiation Lab at IRB Barcelona, talking about his study in...

<p>Angel R. Nebreda.</p>
12 Apr 2017 - Radio Benavente

Angel R. Nebreda, ICREA Research professor and group leader of the Signalling and Cell Cycle Laboratory at IRB Barcelona, was invited by Radio Benavente (Cadena SER) to talk about his career as a Molecular Biologist, his research in cell biology and his ERC Proof of Concept grant to investigate new breast cancer therapies.

During the interview, Angel R. Nebreda gives an advice to young students who want to become scientists: “Scientific research demands a lot of curiosity, you have to be interested in the unknown, ask when you don't understand something, and be strongly motivated”.

In response to a question about the role of science in Spanish society, he says: “We have to...

<p>"A mouse pancreas imaged with selective plane illumination microscopy, a technique that will be used at EMBL Barcelona". Image: Ahlgren, Mayer &amp; Swoger/CRG.</p>
11 Apr 2017 - Science Magazine

Science Magazine publishes a report on the official launch of European Molecular Biology Laboratory's (EMBL) sixth site, in Barcelona. The new branch, housed at the Barcelona Biomedical Research Park (PRBB), will focus on tissue biology and disease modelling.

The agreement between the EMBL and the Spanish government strengthens Barcelona's profile as one of southern Europe's premier science hubs, stresses Joan Guinovart, director of the Institute for Research in Biomedicine, in Science Magazine. “Barcelona is already one of the hottest spots in biomedicine in Europe," he adds.

Link to ...

<p>Image: Julio Carbó.</p>
4 Apr 2017 - El Periódico

The newspaper "El Periódico" has reported on an IRB Barcelona research project on Friedreich’s ataxia disease, funded by the patient and family association, the Babel Family, and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF). The disease is caused by a defect in a gene, frataxin, which results in reduced levels of this protein in the body, particularly affecting the brain, spinal cord and muscles.

The project aims to develop an injectable frataxin treatment that can reach the brain, "like the injection of insulin for diabetics", explains Ernest Giralt,...

<p>Copyright: Panos.</p>
3 Apr 2017 - SciDev.Net

A leading source of news, views and analysis on information about science and technology for global development, SciDev.Net, reports on the research performed by IDIBAPS and IRB Barcelona scientists.  

In the study, co-led by Raúl Méndez, ICREA researcher at IRB Barcelona, and Cristina Fillat, head of the Gene Therapy and Cancer Group at IDIBAPS, researchers have designed a new strategy to achieve genetically modified viruses that selectively attack tumor cells without affecting healthy tissues. 

“What makes our approach different is the mechanism by which the virus acquires oncoselectivity,” Cristina Fillat explains to SciDev.Net.

Link to ...

<p>Image: PATRICK SEEGER/AFP/Getty Images.</p>
2 Apr 2017 - FORBES

High impact in the international media of Ernest Giralt's latest work presented at the meeting of the American Chemical Society in San Francisco. Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, is working on transforming a protein from bee venom into a tool that helps treatments get inside the brain. 

“We thought that because the venoms of some animals are able to attack the central nervous system, they should be able to go through the blood-brain barrier and possibly shuttle drugs across it," explains Giralt. 

Link to ...

<p>Copyright: Getty Images.</p>
2 Apr 2017 - The Huffington Post

The Huffington Post publishes an extensive report on cancer-causing mutations, with a special focus on random DNA errors that occur when self-renewing cells divide, according to a recent paper published in Science by researchers at Johns Hopkins University. 

The report includes declarations of several experts on cancer studies, among them IRB Barcelona research associates Elena Sancho, in the Colorectal Cancer Lab, and Gloria Pascual, in the Stem Cells and Cancer Lab. "Does this means that we can do as we please because whatever we do, we'll have the same probability of having cancer? The answer is a resounding no", stresses Elena Sancho. 

Link to ...